LAPORTE KATHLEEN — SEC Form 4 filings
SEC reporting owner CIK 1196201. 31 Form 4 filings on record with FilingPulse; latest filed 2026-07-21.
Transaction summary — filings shown
Covers all 31 filings on record, filed 2024-02-05 to 2026-07-21. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 6,152 shares, $123,409 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 73.
- Largest priced transaction: sale of 6,152 shares @ $20.06 ($123,409) in Precipio, Inc., filed 2025-09-10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Precipio, Inc. (PRPO) | Director | 9 | — | 1 leg · 6,152 sh · $123,409 | 27 |
| Bolt Biotherapeutics, Inc. (BOLT) | Director | 4 | — | — | 17 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | Director | 9 | — | — | 11 |
| Q32 Bio Inc. (QTTB) | Director | 6 | — | — | 11 |
| 89bio, Inc. (ETNB) | Director | 3 | — | — | 7 |
Form 4 filings — LAPORTE KATHLEEN
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-21 | 4/A | Q32 Bio Inc. (QTTB) | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Q32 Bio Inc. (QTTB) | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Bolt Biotherapeutics, Inc. (BOLT) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Q32 Bio Inc. (QTTB) | Grant/award (A): 23,272 (derivative) @ $2.75 | EDGAR |
| 2026-01-20 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 520 @ $24 | EDGAR |
| 2026-01-09 | 4 | CERO THERAPEUTICS HOLDINGS, INC. (CERO) | Grant/award (A): 690,900 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2025-12-16 | 4 | Bolt Biotherapeutics, Inc. (BOLT) | Grant/award (A): 1,392 (derivative) · Disposition to issuer (D): 1,392 (derivative) · Grant/award (A): 1,250 (derivative) · Disposition to issuer (D): 1,250 (derivative) · Grant/award (A): 1,250 (derivative) · Disposition to issuer (D): 1,250 (derivative) · +8 more | EDGAR |
| 2025-10-30 | 4 | 89bio, Inc. (ETNB) | Disposition to issuer (D): 25,000 (derivative) @ $0 · Disposition to issuer (D): 12,500 (derivative) @ $0 · Disposition to issuer (D): 27,400 (derivative) @ $0 · Disposition to issuer (D): 45,150 (derivative) @ $0 · Disposition to issuer (D): 56,400 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | Q32 Bio Inc. (QTTB) | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-10-16 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 711 @ $17.58 | EDGAR |
| 2025-09-10 | 4 | Precipio, Inc. (PRPO) | Sale (S): 6,152 @ $20.06 | EDGAR |
| 2025-07-02 | 4 | Bolt Biotherapeutics, Inc. (BOLT) | Grant/award (A): 1,100 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | CERO THERAPEUTICS HOLDINGS, INC. (CERO) | Grant/award (A): 9,326 (derivative) @ $0 | EDGAR |
| 2025-04-17 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 2,232 @ $5.60 | EDGAR |
| 2025-03-06 | 4 | CERO THERAPEUTICS HOLDINGS, INC. (CERO) | Grant/award (A): 17,923 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | Q32 Bio Inc. (QTTB) | Disposition to issuer (D): 5,431 (derivative) @ $0 · Grant/award (A): 5,431 (derivative) @ $0 · Disposition to issuer (D): 1,947 (derivative) @ $0 · Grant/award (A): 1,947 (derivative) @ $0 · Disposition to issuer (D): 12,767 (derivative) @ $0 · Grant/award (A): 12,767 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | CERO THERAPEUTICS HOLDINGS, INC. (CERO) | Grant/award (A): 127,500 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | 89bio, Inc. (ETNB) | Grant/award (A): 56,400 (derivative) @ $0 | EDGAR |
| 2025-01-16 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 1,000 (derivative) @ $0 | EDGAR |
| 2024-12-04 | 4 | CERO THERAPEUTICS HOLDINGS, INC. (CERO) | Grant/award (A): 127,500 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | CERO THERAPEUTICS HOLDINGS, INC. (CERO) | Option exercise (M): 965,997 · Option exercise (M): 50 (derivative) @ $1,000 | EDGAR |
| 2024-09-06 | 4 | Precipio, Inc. (PRPO) | Disposition to issuer (D): 75 (derivative) @ $0 · Grant/award (A): 75 (derivative) @ $0 · Disposition to issuer (D): 188 (derivative) @ $0 · Grant/award (A): 188 (derivative) @ $0 · Disposition to issuer (D): 250 (derivative) @ $0 · Grant/award (A): 250 (derivative) @ $0 · +14 more | EDGAR |
| 2024-06-25 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 1,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Bolt Biotherapeutics, Inc. (BOLT) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 9,693 @ $6.70 | EDGAR |
| 2024-03-27 | 4 | Q32 Bio Inc. (QTTB) | Grant/award (A): 12,767 (derivative) @ $0 | EDGAR |
| 2024-03-27 | 4 | CERO THERAPEUTICS HOLDINGS, INC. (CERO) | Grant/award (A): 112,500 (derivative) @ $0 | EDGAR |
| 2024-02-21 | 4/A | CERO THERAPEUTICS HOLDINGS, INC. (CERO) | Grant/award (A): 50 (derivative) @ $1,000 | EDGAR |
| 2024-02-16 | 4 | CERO THERAPEUTICS HOLDINGS, INC. (CERO) | Other (J): 5,828 · Grant/award (A): 50 (derivative) @ $1,000 | EDGAR |
| 2024-02-05 | 4 | 89bio, Inc. (ETNB) | Grant/award (A): 45,150 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1196201 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →